Your healthcare provider should do blood tests to check how well your liver is working before you begin treatment with IXEMPRA and as needed during treatment. If blood tests show that you have liver problems, do not receive injections of IXEMPRA along with capecitabine. If you have liver problems, taking these medicines together could increase your chance of serious infection and death due to a very low white blood cell count (neutropenia).
You should not have your injection of IXEMPRA if you are allergic to medicines that contain Cremophor® EL* (polyoxyethylated castor oil) or if you have a low white blood cell count or a low platelet count. Continue to full Important Safety Information
When considering your next treatment for metastatic breast cancer, see if IXEMPRA—an FDA-approved medicine—is right for you.
Learn if it is an option for you.
Learn what that can mean.
you can use during your treatment with IXEMPRA.
IXEMPRA is a prescription medicine used to treat locally advanced or metastatic breast cancer following certain treatments. IXEMPRA can be used alone or with another cancer medicine called Xeloda® (capecitabine).
Please see the complete Important Safety Information, including boxed WARNING regarding liver disease.
IXEMPRA is a trademark of Bristol-Myers Squibb Company. *Cremophor is a registered trademark of BASF AG. Xeloda is a registered trademark of Roche Laboratories. © 2010 Bristol-Myers Squibb, Princeton, New Jersey 08543 U.S.A. All rights reserved.
691US09WA1490110/10
Cancer that has spread from the breast to nearby tissue or lymph nodes
Cancer that has spread from the breast to other parts of the body